M42 is an Abu Dhabi-based health technology and life sciences company that makes strategic direct investments alongside its healthcare, AI, genomics, digital health and biobank operations. It has acted as a lead investor in a UK Series B1 therapeutics financing, making it relevant for later-stage HealthTech, Biotechnology, Life Sciences, Pharmaceuticals, and AI/data-driven health companies seeking strategic capital.